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We introduce a tensor-based clustering method to extract sparse, low-dimensional structure from
high-dimensional, multi-indexed datasets. This framework is designed to enable detection of clusters
of data in the presence of structural requirements which we encode as algebraic constraints in a linear
program. Our clustering method is general and can be tailored to a variety of applications in science
and industry. We illustrate our method on a collection of experiments measuring the response of
genetically diverse breast cancer cell lines to an array of ligands. Each experiment consists of a
cell line-ligand combination, and contains time-course measurements of the early-signalling kinases
MAPK and AKT at two different ligand dose levels. By imposing appropriate structural constraints
and respecting the multi-indexed structure of the data, the analysis of clusters can be optimized for
biological interpretation and therapeutic understanding. We then perform a systematic, large-scale
exploration of mechanistic models of MAPK-AKT crosstalk for each cluster. This analysis allows
us to quantify the heterogeneity of breast cancer cell subtypes, and leads to hypotheses about the
signalling mechanisms that mediate the response of the cell lines to ligands.
Keywords: Algebra; Tensors; Data clustering; Signaling networks; Systems biology; Model selection and
parameter inference
Muti-dimensional datasets are prevalent across the sci-
ences; their ubiquity and importance will only continue to
grow [1–4]. The ever-increasing sophistication of datasets
requires the development of methods that preserve multi-
dimensional structures and exploit them, whilst main-
taining interpretability of results. In addition, clustering
biological data is far from a straightforward task. There
are multiple challenges, including choosing an appropri-
ate method for the data [5], handling high-dimensional
data [6, 7] and, importantly, the consideration of the bi-
ological context of the problem, which must be done al-
most on a case-by-case basis [8].
Amongst the wide variety of clustering methods, con-
strained clustering is an active field of research [9–
13]. The most common approaches incorporate pair-
wise must-link and cannot-link constraints to indicate
whether two items must or must not be in the same clus-
ter [14, 15]. Other methods set constraints on what the
possible clusters can be, rather than constraining the el-
ements in a cluster [16]. In these cases, there is a large
pool of candidate clusters from which those that meet
selection criteria can be chosen.
In this work we introduce a versatile data clustering
framework based on tensors and algebra to analyze high-
dimensional datasets. One key feature of our method is
that it can incorporate general, application-specific con-
straints on the composition of clusters, and is guaran-
teed to find optimal partitions. The flexibility of the
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method allows it to be used directly on a dataset (i.e.,
as a standalone clustering tool), or in combination with
other clustering methods.
We showcase our clustering framework on an exten-
sive set of time-course measurements of the activation
levels of the mitogen-activated protein kinase (MAPK)
and phosphoinositide 3-kinase (PI3K) pathways that are
involved in cellular decisions and fates [10–13], and are
known to dysfunction in cancer [16, 22–25]. The key sig-
naling proteins and subtype responses in breast cancer
cells are known; however, among genetically diverse cell
lines the specific dysfunction mechanisms vary and are
not well understood [1, 27, 28]. We examine a set of ex-
perimental data [1] containing the response of 36 breast
cancer cell lines after exposure to 14 ligands (growth fac-
tors/signaling molecules). Each experiment measures the
temporal phosphorylation response of one cell line to one
ligand. Because the dataset is complete (i.e., there is a
measurement for every combination of times, proteins,
cell lines, ligands, and doses), we can represent it as a
tensor in five dimensions (Fig. 1A).
We find clusters of experiments subject to inter-
pretability constraints (Fig. 1B,C). Our objective is to
attribute differences between clusters to differences in
the underlying signaling mechanisms, so the composition
of the clusters must facilitate mechanistic interpretation.
For example, the cell lines in a cluster could share a mu-
tation, and the ligands are those whose effect is altered
by the mutation. For this reason, we constrain the clus-
ters to be rectangular, i.e. to match a subset of cell lines
with a subset of ligands (Fig. 2). The constraints help to
rule out similarities between experimental measurements
that are incompatible with a mechanistic interpretation.
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2The interpretability constraints take the form of algebraic
inequalities.
We introduce a new notion of tensor similarity, which
we employ to find optimal clusterings. The global opti-
mality of the partitions is guaranteed by leveraging re-
sults from integer programming. One of the strengths of
this approach, is that it can incorporate a pre-existing
non-rectangular partition obtained with other methods
(e.g., conventional agglomerative clustering, k-means,
spectral methods, community detection on graphs) and
find the nearest optimal rectangular clustering. The dis-
tance between partitions is given by the number of ex-
periments whose clustering assignment changes. Hence
this method can be used in conjunction with any other
state-of-the-art method and preserve the features that
are compatible with the constraints. Moreover, using the
method from an initial partition is computationally ad-
vantageous. The partition into clusters can be visualized
by color coding the grid of experiments according to their
cluster assignment (Fig. 1C). Each box on the grid repre-
sents the cluster assignment of an entire vector (or even
a tensor) of data.
Once we obtain an optimal partition of the data, the
second stage of our analysis is to search for mechanisms
that can explain the behavior of the experiments in each
cluster. We perform a systematic search for nonlinear
ordinary differential equation (ODE) models that repro-
duce the key dynamical features of the time series in each
cluster (Fig. 1D). To this end, we construct, parametrize,
and rank models for each cluster from a pool of 729 can-
didate models.
I. TENSORS AND ALGEBRA
Data tensor. We represent a multi-indexed dataset
(e.g., the complete dataset in Fig. 1A) as a tensor Z
of order h in the real numbers with size n1 × . . . × nh
(i.e., Z ∈ Rn1×...×nh , where ni ∈ N, and i = 1, . . . , h).
When the data is complete, every entry of the tensor
is filled with a number. A full treatment of tensors is
available in [1] and references therein. We introduce here
the tensor theory required for our analysis.
Similarity tensors. In a similarity matrix the entry
(i, j) records the pairwise similarity of the two items la-
belled by unidimensional indices i and j. We now intro-
duce the high-dimensional generalization of a similarity
matrix, which extends this to multi-indexed data. Sup-
pose we want to compute the similarity of the data in-
dexed by i = (i1, i2) and indexed by j = (j1, j2):
si,j = sim (Z(i1, i2, :, . . . , :), Z(j1, j2, :, . . . , :)) , (1)
where i1, j1 ∈ {1, . . . , n1} and i2, j2 ∈ {1, . . . , n2}. The
similarity function sim : Rn3×···×nh × Rn3×···×nh → R
computes the similarity between the data indexed by i
and j (e.g., correlation or cosine similarity). In general,
for data indexed by the first d dimensions, we have the
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FIG. 1. Schematic of constrained tensor clustering method
and model identification. (A) The complete set of experi-
ments can be represented by the multi-indexed tensor Z; see
Data section. (B) The similarity scores between experiments
(each cell line/ligand combination) can be stored in a sim-
ilarity matrix S˜, that can be used to construct a similarity
tensor S, or to find a preliminary clustering of the data W
that may not comply with the constraints. (C) Structured
clustering via integer programming. The starting point can
either be the similarity tensor S or the pre-existing cluster-
ing W. The possible clusterings are represented by points on
the grid. The red line is the value of the objective function
(equations 6 and 7). The best integer value (orange point)
is found inside the convex feasible region (blue). (D) A large
scale search for mechanistic models for each cluster involves
parametrising, and ranking the best ODE models for each
cluster.
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FIG. 2. Examples of cluster shapes that are allowed and not
allowed in our analysis of breast cancer data. The clusters
on the first two columns are all rectangular, and thus allowed
under our interpretability framework. The third column con-
tains examples of non-rectangular clusters that are not al-
lowed in our framework. Note that j is not necessarily equal
to i+ 1, and k is not necessarily h+ 1.
multi-indices i = (i1, . . . , id) and j = (j1, . . . , jd). The
dimensions of Z can be re-ordered as needed. We can
construct a similarity tensor S of order 2d. The shape
of S is determined by the chosen dimensions of the data:
S ∈ Rn1×...×nd×n1...×nd . The similarity tensor and the
similarity matrix are related by flattening the tensor as
follows. The original data tensor Z can be flattened (re-
shaped) into a data matrix Z˜ ∈ RN1×N2 , where N1 =∏d
r=1 nr, and N2 =
∏h
r=d+1 nr. Each row of Z˜ is a N2-
dimensional vector that corresponds to multi-index i, and
the length N2 is the product of the dimensions of Z that
are not included in i.
The similarity matrix between the rows of Z˜ is S˜ ∈
RN1×N1 , which is obtained by flattening the similarity
tensor, S. We summarize this relationship in the follow-
ing diagram:
Z S.
Z˜ S˜
flatten
similarity of i and j
similarity of rows
reverse flatten
To compute the similarity tensor S, we can simply flatten
the data tensor Z into Z˜, construct a similarity matrix
S˜, and then reverse flatten it into the desired S. Note
that Z and S have the same number of entries as Z˜ and
S˜ respectively.
Example. Let Z ∈ R10×5×3 be a tensor of order 3. If
i = (i1, i2) is the multi-index, then d = 2, N1 = 10 · 5 =
50, and N2 = 3. The (order 4) similarity tensor S has
size 10 × 5 × 10 × 5. The similarity matrix S˜ has size
50× 50. The flattened data matrix Z˜ has size 50× 3.
Algebraic interpretability condition. When clustering
a set of data points we typically seek to find a partition
such that the points within a cluster are more similar (or
close) to each other than to the rest of the data [5]. In the
simplest cases, there are few restrictions on the clusters
other than that the similarity or distance be reflected
in the cluster assignments. In certain cases, imposing
restrictions on the clusters can be desirable or even re-
quired [11]. Here we pursue structured clustering; that
is, we impose restrictions on the shape of the clusters in
the tensor. In this application, we seek clusters with a
rectangular shape which allows us to interpret clusters
in terms of data-generating mechanisms (i.e., grouping
cell lines/ligand combinations to ensure mechanistic in-
terpretation). We describe the biological motivation for
these constraints in the results section (Sec. IV A) and
the mathematical details of the method here.
A hard partition of a dataset represented as a tensor
Z of size n1 × · · · × nh into m clusters can be encoded in
two ways:
1. An (n1 × . . . × nd) × (n1 × . . . × nd) tensor X in
which the data have multi-indices i = (i1, . . . , id)
and j = (j1, . . . , jd), and:
xij =
{
0 if i and j belong to the same cluster,
1 otherwise.
(2)
The tensor X can be seen as a Boolean approxima-
tion of the distances between pairs of data points:
xij = 0 if i and j are ‘close’ (in the same cluster),
and xij = 1 if they are ‘far’ (in different clusters).
To ensure that X encodes a valid clustering of the
data, the three conditions of an equivalence rela-
tion must be met. These conditions are given by
the following algebraic equations and inequality:
Reflexivity: xii = 0,
Symmetry: xij = xji, (3)
Transitivity: 0 ≤ −xik + xij + xjk ≤ 2.
2. In a n1 × . . .× nd ×m tensor Y, where
yik =
{
1 if the data indexed by i belongs to cluster k,
0 otherwise.
(4)
We require that
∑m
k=1 yik = 1, to ensure that each
data item has been assigned to exactly one cluster.
4The tensors X and Y are related by the following equa-
tion:
1− xi,j =
m∑
k=1
yi,kyj,k.
Integer Optimization. The structural or interpretabil-
ity conditions we have imposed on the clusters take the
form of linear constraints. These constraints, along with
the fact that the tensors are Boolean, allow us to find
optimal tensors X and Y by solving an integer linear
program [29, 30]. Specifically, we use the branch and cut
algorithm [31] as we describe in the Structured clustering
section below.
II. DATA
We examine an extensive experimental dataset detail-
ing the temporal phosphorylation response of signaling
molecules in genetically diverse breast cancer cell lines in
response to different growth factors [1]. This dataset is
complete and can be represented by a tensor Z of order 5
whose dimensions correspond to 36 cell lines, 14 ligands,
two doses, three time points, and two proteins (pERK,
pAKT) (see the SI Appendix for more details). In this
work each experiment is a set of measurements (for all
time points, doses, and proteins) for each cell line/ligand
combination (36 · 14 = 504 experiments). Our goal is to
find sets of experiments with a similar response; conse-
quently, the data structures we require are the following:
Z ∈ R36×14×2×3×2, (data tensor)
Z˜ ∈ R504×12, (flattened data tensor)
S ∈ R36×14×36×14, (similarity tensor)
S˜ ∈ R504×504. (similarity matrix)
Each experiment has a multi-index i = (i1, i2), where
i1 ∈ {1, . . . , 36} and i2 ∈ {1, . . . , 14}. We compute the
504 × 504 cosine similarity matrix S˜ of the normalized
rows of Z˜ (see SI Appendix, II.B and II.C).
III. STRUCTURED CLUSTERING
Given a similarity tensor S, we seek the best partition
of experiments subject to the interpretability constraints:
clusters be rectangular with respect to cell lines and lig-
ands (see eq. (5) and results section). This approach is
similar to those in Ref. [7]; however, we do not require
the rectangles to be connected. This is because we do
not require a fixed order for the rows and columns of the
data. This is an important strength of our method: an
ordering of the data is artificial, and we seek clustering
results that are not biased by order.
We present two implementations of our method. The
first one does not require previous knowledge about the
clustering assignment of the experiments, and provides
an optimal clustering directly from the similarity data.
However, owing to the high computational costs of per-
forming integer programming, this variant of our method
is only appropriate for small datasets. The computations
can be sped up by employing heuristics for the integer
optimization, see for example Ref. [32].
To tackle larger datasets, we present a second imple-
mentation that begins with a pre-existing partition of the
experiments into clusters (not necessarily compliant with
the constraints), which might originate from any cluster-
ing method (e.g., using the reshaped similarity tensor
S˜). This implementation then reconstructs S and finds
the nearest optimal clustering compliant with the con-
straints. Starting with an initial clustering has the ad-
vantage that we can employ the best methods for clus-
tering a particular type of data, whose results we then
refine to find clusters that are compatible with the in-
terpretability condition. The initial clustering must be
chosen carefully to fit the application, and should not be
viewed as merely an initialization of the algorithm. Pair-
ing our method with a pre-existing clustering also has
the advantage that it significantly reduces computational
cost (see SI Appendix, Figure 7).
A. No prior clustering
When we do not have any prior clustering of the exper-
iments, we work directly on the similarity tensor S. The
entries of this tensor record the similarity of experiments
i and j, where i = (i1, i2), j = (j1, j2), where the ranges
of indices are i1, j1 ∈ {1, . . . , 36} and i2, j2 ∈ {1, . . . , 14}.
The clustering assignments are recorded by the ten-
sor X defined in equation (2). The rectangular-shaped
interpretability condition corresponds to three types of
algebraic constraints on the entries of X:
xi1i2j1j2 = xi1j2j1i2 ,
0 ≤ xi1i2j1j2 − xi1i2j1i2 ≤ 1, (5)
0 ≤ xi1i2j1j2 − xi1i2i1j2 ≤ 1.
We search over arrays X that satisfy these conditions.
The experiments in the same cluster should have high
similarity, so we maximize the similarity between exper-
iments in the same cluster. This maximization is equiv-
alent to solving the integer optimization problem
max
X
〈S, (1−X)〉+ λ〈1,X〉, (6)
subject to bl ≤ V · vec(X) ≤ bu,
where the tensors X and S are as above, 〈·, ·〉 denotes the
entry-wise inner product, and · represents matrix multi-
plication of the matrix V by the vector vec(X). The
5042 × 1 vector vec(X) is the vectorized form of X, and
1 is the tensor of ones with the same size as X. The
5coefficient λ is a regularization term introduced to con-
trol the number of clusters. The matrix V encodes the
constraints on X given in eq. (3) and eq. (5). This ma-
trix has over 1 million rows, 5042 columns and is ex-
tremely sparse. The kth row of V represents the kth
constraint on the values of vec(X): the entry is the coef-
ficient (which can be 0, 1, or −1) with which each entry
of vec(X) appears in the constraint. The kth entry of
bl and bu (which can be 0, 1, or 2) give the lower and
upper bounds respectively of each linear inequality. We
solve this optimization program using the branch and cut
algorithm [31] via the IBM ILOG CPLEX Optimization
Studio [33].
The resulting rectangular clusters are a sparse, low-
rank representation of the data. The tensor 1−X, of size
(36×14)×(36×14), gives a binary measure of the distance
between any two experiments. This tensor has sparse
block structure: it consists of m cuboids of 1s along the
diagonal, where m is the number of clusters, and has
zeros everywhere else. As a consequence X has low mul-
tilinear rank [34], bounded above by (m,m,m,m), which
is less than the maximum possible value of (36, 14, 36, 14).
B. Pre-existing clusters
When we have a pre-existing or initial non-rectangular
clustering of the experiments, we find the nearest struc-
tured clusters using linear integer optimization. The in-
put to this method is an initial partition of the 504 ex-
periments into m clusters. We then modify the cluster
assignments to reach the closest possible interpretable,
structured clustering.
The initial clustering is encoded by a partition tensor,
W, of size 36× 14×m
wik =
{
1, i is in cluster k,
0, otherwise,
where i = (i1, i2) indexes an experiment. The new clus-
ters are encoded by a tensor Y of the same size (defined
according to equation (4)). In order to have rectangular
clusters, the entries of Y must satisfy the conditions
m∑
r=1
yijr = 1, (unique cluster assignment)
−1 ≤ yikr + yjlr − yilr ≤ 1. (interpretability condition)
As before, we use the branch and cut algorithm to ob-
tain the global optimum (given W) for the optimization
problem
max
Y
〈W,Y〉. (7)
The inner product 〈W,Y〉 sums the number of cluster-
ing assignments unchanged by converting the initial un-
structured clustering into a clustering that satisfies the
interpretability constraints.
We obtain the tensor Y, of size 36× 14×m by solving
the optimization problem in eq. (7). As with X, the
tensor Y also has sparse and low-rank structure. Its m
two-dimensional slices, each a matrix of size 36×14, have
rank two and block structure with a rectangle populated
by 1s and all other values equal to 0.
IV. RESULTS
A. Biological interpretation of constraints
Each experiment in our data is indexed by (ci, lj),
where ci is the ith cell line, and lj is the jth ligand.
A high similarity between experiments suggests the pos-
sibility of a common underlying biological mechanism.
This is the basic notion that underpins the constraints in
our clustering method which force the clusters to pair a
subset of the cell lines with a subset of the ligands in such
a way that each cluster must be rectangular, although
possibly disconnected (Fig. 2). The motivation behind
this constraint is to enable the interpretation that the
experiments in each cluster are generated by the same
biological mechanism (e.g., if they share a feature such
as a genetic mutation). The difference between our con-
strained approach and conventional clustering is that in
the latter a high similarity is enough to cluster two ex-
periments together. In our approach similarity alone is
not enough, we also require that the observations admit
the same mechanistic interpretation. For example, sup-
pose that two experiments (ch, li) and (ck, lj) belong to
the same cluster. If we swapped the ligands (i.e., we
looked at the experiments in the diagonally opposite en-
tries (ck, li) and (ch, lj)), under the assumption that the
cell lines share the same signalling mechanism, these ex-
periments should also be in the same cluster because we
expect them to respond in a similar way (see left columns
of Fig. 2). If, however, (ch, li) and (ck, lj) are clustered
together but (ck, li) and (ch, lj) are not in the same clus-
ter (see right column of Fig. 2), it would be more difficult
to assign mechanistic interpretations to the clusters.
B. Interpretable groups by mutation and receptor
subtype
In a clinical setting, prognosis and treatment decisions
for breast cancer are guided by tumor grade, stage and
clinical subtype [35], which is based on the presence of
cellular receptors:
• HER2amp cells are characterized by amplification
of the HER2 gene, leading to over-expression of the
ErbB2 receptor tyrosine kinase;
• HR+ cells are characterized by the expression of
the estrogen receptor (ER) or progesterone receptor
(PR);
6y
BT
C
EG
F
EP
R
FG
F-1
FG
F-2 HG
F
HR
G
IGF
-I
IGF
-II INS
NG
F-b
eta
PD
GF
-BB SC
F
VE
GF
16
5
SK-BR-3
AU565
BT-474
HCC1419
HCC1569
HCC1954
HCC202
MDA-MB-361
UACC-893
ZR-75-30
UACC-812
HCC1500
MDA-MB-134-VI
MCF7
BT-483
CAMA-1
HCC1428
MDA-MB-415
T47D
ZR-75-1
MDA-MB-175-VII
BT-549
HCC1395
HCC1806
MDA-MB-436
MDA-MB-453
MDA-MB-468
MDA-MB-231
BT-20
HCC1937
HCC38
HCC70
MDA-MB-157
HCC1187
184B5
Hs 578T
BT
C
EG
F
EP
R
FG
F-1
FG
F-2 HG
F
HR
G
IGF
-I
IGF
-II INS
NG
F-b
eta
PD
GF
-BB SC
F
VE
GF
16
5
MCF7
BT-483
CAMA-1
HCC1428
MDA-MB-134-VI
MDA-MB-175-VII
MDA-MB-415
T47D
ZR-75-1
HCC1500
BT
C
EG
F
EP
R
FG
F-1
FG
F-2 HG
F
HR
G
IGF
-I
IGF
-II INS
NG
F-b
eta
PD
GF
-BB SC
F
VE
GF
16
5
MDA-MB-231
BT-20
BT-549
HCC1395
HCC1806
HCC1937
HCC38
HCC70
Hs 578T
MDA-MB-157
MDA-MB-436
MDA-MB-453
MDA-MB-468
184B5
HCC1187
y
BT
C
EG
F
EP
R
FG
F-1
FG
F-2 HG
F
HR
G
IGF
-I
IGF
-II INS
NG
F-b
eta
PD
GF
-BB SC
F
VE
GF
16
5
SK-BR-3
AU565
BT-474
HCC1419
HCC1569
HCC1954
HCC202
MDA-MB-361
UACC-893
ZR-75-30
UACC-812
HCC1500
MDA-MB-134-VI
MCF7
BT-483
CAMA-1
HCC1428
MDA-MB-415
T47D
ZR-75-1
MDA-MB-175-VII
BT-549
HCC1395
HCC1806
MDA-MB-436
MDA-MB-453
MDA-MB-468
MDA-MB-231
BT-20
HCC1937
HCC38
HCC70
MDA-MB-157
HCC1187
184B5
Hs 578T
D
A
C
H
ER
2a
m
p
TNBCB
ce
ll 
lin
es
ligands ligands
HR+
H
R+
TN
BC
H
ER
2a
m
p
H
R+
TN
BC
FIG. 3. Tensor-based structured clustering. (A) TNBC clustering with no prior clustering information. (B) HR+ clustering
with no prior information. (C) Clustering of all cell lines starting from an initial partition into three clusters. (D) Clustering
from an initial partition into five clusters. Note that the colours on the grid represent clustering assignments, and are not
reflective of the intensity of any single parameter.
• Triple negative breast cancer (TNBC) cells are neg-
ative for HER2 amplification, and express ER and
PR at low levels.
We compare the clusters from our method with the
three standard clinical subtypes above. We also com-
pare our clusters with the mutational status of the cell
lines [36, 37], and with their drug response [38], and with
the findings from the previous clustering and analysis of
this data set, found in [1].
We first investigate a fine-grained classification within
each of the three clinical subtypes. A summary statistic
between 0 and 1 (based on the cosine similarity, see SI
Appendix II.B) quantifies the within-class variation for
each clinical subtype. A score of 0 indicates complete ho-
mogeneity, and 1 indicates complete heterogeneity. The
HER2amp cell lines show comparatively little variation,
with an average difference score of 0.086. The TNBC
and the HR+ cell lines have an average difference score
of 0.224 and 0.334. We obtained clusters without prior
knowledge of an initial clustering by solving the opti-
mization problem (6). The results (shown in Fig. 3A,B)
identify heterogeneity within each subtype as well as cell
lines of particular interest.
Figure 3A shows the clustering of the HR+ cell lines.
Cell line MDA-MB-415 stands out for its response to
so-called high-response ligands [1] (ligands to the left of
HRG in Fig. 3B). Among all cell lines, MDA-MB-415 has
the second highest susceptibility to the drugs Ixabepi-
lone, Methylglyoxal and PD [38]. CAMA-1 cell line is
distinctive in its response to the low-response ligands (to
the right of HRG), which might help explain why it is
particularly susceptible to both (Z)-4-Hydroxytamoxifen
and TCS PIM-11 [38]. The TNBC cell lines are divided
into 12 clusters (Fig. 3B), which mirror the heterogeneous
behavior of TNBC in the clinic [39]. All but one TNBC
cell lines with a PTEN mutation appear in the green clus-
ter. The only exception is the HCC1937 cell line, which
has a PTEN mutation but appears in the yellow clus-
ter. The cluster assignment of cell lines MDA-MB-231
and MDA-MB-157 is markedly different from that of the
other cells across the ligands. These assignments might
be explained by the mutational status of the cell lines;
MDA-MB-231 is the only cell line with an NF2 mutation
or a BRAF mutation, whereas MDA-MB-157 is the only
cell line with an NF1 mutation. The bright orange clus-
ter contains five cell lines (all but HCC1937) with the
same two CDKH2A mutations.
The HER2amp cell lines cluster together for all lig-
ands except for the MDA-MB-361 cell line. This is the
HER2amp cell line most resistant to HER2-targeted ther-
apy such as Lapatinib [38]. In fact, its resistance to La-
patinib exceeds that of some TNBC cell lines (HCC2185
and MDA-MB-453). The grouping of the rest indicates
the consistency among all other HER2amp cell lines (see
SI Appendix II.B).
Clustering all cell lines. To cluster all cell lines we
solve the optimization problem (7) which requires an ini-
tial “seed” clustering of the experiments. We obtained
our initial clustering by first constructing a graph of ex-
periments from the similarity matrix S˜ using the Relaxed
7Minimum Spanning Tree algorithm [2–4]. Then we used
the Markov Stability community detection method [5, 6]
to find robust partitions of the experiments into three,
five and seven groups (see SI Appendix, Fig. 3).
From the initial partition into three clusters, we obtain
three rectangular clusters (Fig. 3C). These groups respect
the broad division of the cell lines seen in Fig. 3A,B,
which is a sign of the consistency between the two im-
plementations of our method. Of these, we find that
two groups of ligands correspond to previously reported
high active expression profiles (yellow and green) and
one to muted profiles (blue), respectively [1]. Within the
more highly active group, the HR+ cell lines are predom-
inantly in the yellow cluster, while the HER2amp cells
are in the green cluster. This separation of the HR+
and HER2amp clinical subtypes is entirely data driven
and supports the notion that our method is indeed able
to find interpretable groups. The cell lines that are not
clustered according to their subtype reflect previous find-
ings that neither growth factor responses nor sensitivity
to drugs that target signal transduction pathways is uni-
form within clinical subtypes [1, 19, 28]. The TNBC cell
lines are divided between the yellow and green clusters,
providing further evidence of the heterogeneity in TNBC
cell lines [19, 46–50].
When we start from the initial non-rectangular clus-
tering into five groups, the resulting rectangular clus-
ters split the ligands into a low response group (blues)
and high response (green, yellow, brown). This split is
nearly the same as we obtained before (Fig. 3D). Note
that the difference in the ligand HGF may be due to the
fact that it is not part of the ErbB nor the FGF families
of ligands. The HER2amp cell lines are now all assigned
to the green cluster and there are only three HR+ cell
lines not assigned to the yellow cluster. A new brown
cluster consists of cell lines: MDA-MB-175-VII (classi-
fied as a HR+), UACC-812 (HER2amp), 1845B5 (TNBC)
and HS578T (TNBC). While none of them has the same
cell classification or genetic mutation, all cell lines in the
brown cluster show high susceptibility to the drug Gefi-
tinib [38]. Note that MDA-MB-175-VII is the only HR+
cell line that is not assigned to the yellow group in either
three or five clusters; this might be due to the fact that
this cell line carries a unique chromosomal translocation.
The translocation leads to the fusion and amplification
of neuregulin-1 which signals through ErbB2/ErbB3 het-
erodimers [51, 52], and could be the underlying cause of
the cell line’s unique sensitivity to ErbB-targeting drugs
such as Lapatinib or Afatinib [19, 28].
We compare the results from our clustering method to
the original analysis of this data set [1]. In our analysis,
we are able to obtain simultaneously meaningful subsets
of both indices (the cell lines, and the ligands), without
biases given to either index or to the ordering of the data.
In contrast, in the unstructured clusters shown in [1, Fig-
ure 3], the interpretation of the results required aggregat-
ing information to study how the effects vary with each
cell line or with each ligand individually, but not simul-
taneously [1, Figure 4]. Our method allowed the clinical
subtypes to be recovered from the data, based on tempo-
ral responses to a detected subset of the ligands. Excep-
tions to this classification provide biological hypotheses
for possible subsequent investigation. In contrast, the
clinical subtypes were not detectable from the clustering
assignments of the temporal data made in [1, Figure 3].
The clustering that begins from an initial partition into
seven groups shows high consistency with the five cluster
case (see SI Appendix, Figure 6). We therefore continue
our analysis on the five rectangular clusters.
C. Systematic model identification
We now analyze the response of the five structured
groups found in the previous section (Fig. 3D) to obtain
a mechanistic insight about about the cell line/ligand
combinations in each cluster. We consider 729 possi-
ble ODE network models, and then perform systematic
model analysis of the 44 that are structurally identifiable
with the given data. We test structural identifiability,
a prerequisite for performing parameter estimation and
model selection, using Daisy [20]. Then, we parametrize,
rank and choose the models that best represent each clus-
ter’s response. As a result, we have a list of candidate sig-
naling mechanisms for each cluster which provides more
information than the statistical predictions of the sen-
sitivity of MAP Kinase drug targets (e.g., ErbB drug
class) [19].
Models of the MAPK and AKT pathways have been
studied under a variety of biological and modeling as-
sumptions [8, 9, 18], including pathway crosstalk [13, 15–
17]. Here we consider simple models to ensure the param-
eters are at least locally identifiable so there are a finite
number of parameter values to fit the data. We con-
struct nonlinear ordinary differential equation models to
describe the dynamics of the AKT and ERK signaling
pathways. See the SI Appendix for a synopsis of MAPK
models and details of their construction. Briefly, these
models include three molecular species: Receptor (R),
pERK (E) and pAKT (A). Since the data contains the
response of pERK and pAKT, we assume that the re-
ceptor must phosphorylate ERK and/or AKT. We con-
sider positive, negative, or no interaction between pERK
and pAKT under different types of kinetic regimes (mass-
action or Michaelis–Menten) and different types of inhi-
bition (blocking/sequestration or removal/degradation).
The combination of these features results in the 44 struc-
turally identifiable models that we study in further de-
tail. Each model corresponds to a different mechanistic
hypothesis of the dynamics in the pathways (see SI Ap-
pendix III.C). To find the models that best describe the
response of each of the five clusters, we estimate param-
eters using the Squeeze-and-Breathe algorithm [21], and
rank them using the Akaike information criterion score
(AICc) (see SI Appendix IV.D). The best models for each
cluster are shown in Fig. 4.
8Top
2nd
Cluster number
1 2 3 4 5
3rd
4th
EA
R
EA EA EA
R
EA
EA EA EA EA
R
EAEA
R
EA
R
EA
EA EA
R
EA
EA
Model
rank
EA
R
EA
R
EA
L
L
L
L
L
L
L
L
L
L
L
L L
L
L
L
L
L
L L
R
R
R
R R R
R R
RR
R
R
Activation InhibitionLigand Receptor pAKTpERKL R E A
Estimated initial average receptor (x10-1)
R R R
3 - 4      <     < 6 - 7          
Strength of kinetics:
<x10-5 x10-5 x10-4 x10-3 x10-2 x10-1 x100 x101
FIG. 4. The top four models for each cluster according to
the AICc ranking. The strength of interactions are indicated
by the size of the arrow. The grey arrows indicate a blocking
mechanism for inhibition. Black inhibition arrows indicate a
removal mechanism for inhibition.
The AICc, used for model selection, penalizes more
complex models; therefore it is not surprising that the
top models are the simplest ones. The best models for
each cluster have different feedback strengths (parame-
ter values) and network topologies (see Fig. 4); this sup-
ports the hypothesis that mutations may play a role in
the dynamics. Although the values of the parameters
vary, the model with arrows from the receptor (R) to
pAKT and pERK appears in all clusters, which is in line
with how cells are understood to operate. We remark
that cluster 4, which corresponds to HR+ cells (yellow
in Fig. 2D), includes inhibition crosstalk as the second
best model, whereas in all other clusters this mechanism
appears in fourth place. This finding suggests the possi-
bility that the cell lines in cluster 4 share a feature which
is relevant to the ligands that also appear in this clus-
ter. This type of insight is made possible because of the
constraint we have imposed on the clusters.
V. DISCUSSION
We have introduced a novel framework to cluster multi-
indexed data based on tensors that allows structural con-
straints to be incorporated using algebraic relationships.
This method can be used to extract clusters directly from
the data, and if an initial clustering which may not sat-
isfy the constraints is provided, it can find the closest
optimal partition that satisfies the constraints. A key ad-
vantage of this framework is that it allows more control
over the composition of clusters than in many unsuper-
vised methods, and allows the clustering to be tailored to
the requirements of the problem. The main limitation of
this method is that it requires complete data (i.e., a mea-
surement for every cell line/time/dose/ligand/molecule
combination), which can be difficult to obtain. The met-
ric used to compare data points could be adapted to deal
with a small number of missing entries, but the method
is unlikely to perform well for sparse data.
We applied this method on a dataset charting the re-
sponse of genetically diverse breast cancer cell lines to
ligands. We identified both similarities (e.g., HER2amp)
and heterogeneities (e.g., TNBC) within clinical sub-
types. The heterogeneity of our clustering analysis
(Fig. 3B) seems to be related to both the mutational
status of the cells as well as their response to inhibitors.
This result means that similar analyses in patient tissues
might be able to identify patients that respond differently
to therapeutic methods commonly used within a clinical
subtype. By analyzing clusters from all subtypes, we also
showed that we cannot attribute the dynamics of each
data cluster with only one signalling mechanism, which
helps explain network model differences across cell type.
The applicability of our method goes beyond the bi-
ological problem presented here. It can be used in any
context in which the constraints on the clusters can be
expressed in algebraic form (as equalities and inequali-
ties), such as when there are size restrictions on the clus-
ters, or to impose/prohibit particular combinations of
data beyond must-link and cannot-link constraints. For
example, this method could be used to construct opti-
mal portfolios that comply with rules about their com-
position [60], to help the formation of teams that maxi-
mize members’ preferences and are compliant with skill
requirements [61], and to find communities in networks
with quotas, among others. The presented pipeline (a so-
phisticated and interpretable data analysis method that
feeds into a nonlinear modeling framework) will be ever
more necessary as increasingly more large-scale, compre-
hensive datasets become available.
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SUPPLEMENTARY INFORMATION: TENSOR CLUSTERING WITH ALGEBRAIC CONSTRAINTS
GIVES INTERPRETABLE GROUPS OF CROSSTALK MECHANISMS IN BREAST CANCER
Appendix A: Data
We analyse a data set first presented in Ref. [1], which is available for download at the webpage
http://lincs.hms.harvard.edu/niepel-bmcbiol-2014/. The data consists of time course measurements (at 0, 10, 30,
and 90 minutes) of the fold change in the phosphorylation levels of the mitogen activated protein kinase (MAPK)
pERK and the phosphoinositide 3-kinase (PI3K) pAKT in 36 breast cancer cell lines (Table I), each exposed to
two doses (low: 1 ng/ml and high: 100 ng/ml) of 14 different ligands (Table II). Figure S1 shows an example of the
temporal response of pAKT and pERK in the cell line MCF7 to doses of betacellulin.
The data set is complete in the sense that it contains measurements of pAKT and pERK in every cell line, exposed to
2 doses of each of the 14 ligands at 4 time points. As a result, we are able to represent the data as a ×36×14×2×3×2
tensor Z, with entries zijptd. The index p ∈ {pAKT, pERK} denotes which protein was measured, i corresponds to
the cell lines in Table I, j corresponds to the ligands in Table II, d ∈ {1, 100} denotes the doses, and t ∈ {10, 30, 90}
is time after the stimulus.
Appendix B: Clustering
We first describe how we normalize the experimental data for clustering. Then we provide details for how we
clustered directly from the data, and then how we obtained and incorporated an initial clustering.
1. Normalization
We normalize the data as follows. We scale all the pAKT and pERK foldchange responses such that their average
takes each the value 1. This normalization balances the effects of AKT and ERK, so that the behavioural features
and not the scale are the dominating features, and to ensure we treat them with equal significance in our study. The
mean value (pre-normalization) across the AKT responses is 1.7754 and that across the ERK responses is 11.4190.
2. No prior clustering
As a summary statistic of the three clinical subtypes, we compute the average distance score within each subtype.
The score for the 11 HER2amp cell lines is obtained as follows. There are 154 = 11×14 experiments in the dataset that
involve HER2amp cell lines, each consisting of 12 measurements. For each pair of experiments, we find the dissimilarity
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FIG. S1. Time course measurements of cell line MCF7 exposed to two doses of betacellulin (BTC).
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Cell line Subtype
MCF7 HR+
SK-BR-3 HER2amp
MDA-MB-231 TNBC
AU-565 HER2amp
BT-20 TNBC
BT-474 HER2amp
BT-483 HR+
BT-549 TNBC
CAMA-1 HR+
HCC-1395 TNBC
HCC-1419 HER2amp
HCC-1428 HR+
HCC-1569 HER2amp
HCC-1806 TNBC
HCC-1937 TNBC
HCC-1954 HER2amp
HCC-202 HER2amp
HCC-38 TNBC
HCC-70 TNBC
Hs 578T TNBC
MDA-MB-134VI HR+
MDA-MB-157 TNBC
MDA-MB-175VII HR+
MDA-MB-361 HER2amp
MDA-MB-415 HR+
MDA-MB-436 TNBC
MDA-MB-453 TNBC
MDA-MB-468 TNBC
T47D HR+
UACC-812 HER2amp
UACC-893 HER2amp
ZR-75-1 HR+
ZR-75-30 HER2amp
184-B5 TNBC
HCC-1187 TNBC
HCC-1500 HR+
TABLE I. Breast cancer cell lines used in the data set [1].
Ligand name Abbreviation
Betacellulin BTC
Epidermal Growth Factor EGF
Epiregulin EPR
Fibroblast Growth Factor (acidic) FGF-1
Fibroblast Growth Factor (basic) FGF-2
Hepatocyte Growth Factor HGF
Heregulin β1 HRG
Insulin-like Growth Factor 1 IGF-1
Insulin-like Growth Factor 2 IGF-2
Insulin INS
Nerve Growth Factor NGF-beta
Platelet Derived Growth Factor BB PDGF-BB
Stem Cell Factor SCF
Vascular endothelial growth factor A VEGF165
TABLE II. Ligands used in the data set [1].
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Clustering Her2amp straight from the data
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FIG. S2. Clusters from the data of HER2amp cell line.
between the 12 measurements, using cosine dissimilarity
1− 〈v1, v2〉‖v1‖2‖v2‖2 ,
where 〈·, ·〉 is the usual inner product in a real vector space and ‖ ·‖2 is the Euclidean norm. The average dissimilarity
is obtained by averaging these pairwise distances across the
(
154
2
)
= 11781 pairs. Similarly for the HR+ cell lines and
for the TNBC cell lines. The averages obtained are 0.086 for HER2amp, 0.334 for HR+ and 0.224 for TNBC. The
partitioning of the HER2amp cell lines is given in Fig. S2.
3. Pre-existing clusters
a. Computing pre-existing clusters
We find an initial clustering of the experiments. For this initial clustering, we label each experiment by a single
index. The data for the ith experiment is:
Z˜(i, :) =
[
AKT1i
∣∣ ERK1i ∣∣ AKT100i ∣∣ERK100i ] , (B1)
where AKT1i is the normalised time series of fold-change response of pAKT under dose 1ng/ml, and so on. We
compute the 504× 504 similarity matrix S˜, in which sij indicates the cosine similarity of experiments i and j:
sij =
〈z˜i, z˜j〉
||z˜i||2 ||z˜j ||2
= cos (z˜i, z˜j). (B2)
where z˜i = Z˜(i, :) and z˜j = Z˜(j, :). The entries of z˜i and z˜j are nonnegative, which means that sij ∈ [0, 1]. If
sij = 1, experiments i and j have an identical response to the treatments in both AKT and ERK (up to a scaling
constant). When sij = 0, the data for the experiments are orthogonal. The task of clustering the experiments faces
two challenges: the number of clusters is not known a priori, and the matrix S˜ is full matrix and is noisy due to
experimental error. To tackle these challenges we use a combination of tools from manifold learning and network
science. We create a network (graph) in which each of the 504 experiments is represented by a node, and where
connections exist between similar experiments. We first define the dissimilarity matrix D (dij = 1 − sij). We then
use the Relaxed Minimum Spanning Tree (RMST) algorithm [2–4], which extracts a network representation from
high-dimensional point clouds (in this case the z˜i) that are embedded in a lower dimensional manifold.
Specifically, the algorithm creates an undirected, unweighted network with an edge between i and j if they are
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FIG. S3. Number of communities and variation of information for the network obtained from RMST similarity graph.
neighbors in a minimum spanning tree (MST) from D. The algorithm adds extra edges to the network if they
are consistent with the continuity of the data, i.e. if the distances between the points in D is comparable to their
separation in the MST and is consistent with the continuity of the data, according to the equation
dij < mlinkij +
1
2
(ki + kj).
Here mlinkij is the maximal edge weight in the MST path connecting i to j, and ki is the the distance to the nearest
neighbour of i (i.e., the minimum value on the ith row of D, excluding dii). Basically, what the RMST algorithm
does is allows edges to be added to the MST (it ‘relaxes’ the MST), so that we obtain an network description of high
dimensional data that is embedded on a lower dimensional manifold.
Once we have obtained the network from the similarity matrix, we extract communities using the Markov Stability
(MS) community detection algorithm [5, 6]. This method employs continuous time random walks of varying duration
(Markov time) to extract communities of the network at different levels of resolution. Shorter Markov times produce
small communities, whereas longer Markov times lead to coarse partitions of the network. Obtaining the optimal
partition of a network into communities is an NP complete problem, so MS uses heuristics to find communities.
Because there is no guarantee of finding a global optimum, MS repeats the heuristic search 100 times for each Markov
time. The variability in each set of 100 solutions is measured with the Variation of Information (VI) [7]. A low value
of the VI for a Markov time indicates that the solutions obtained are similar to each other, we take this similarity as
a sign that there is a robust partition of the network for this Markov time. In Fig. S3 we show that the network A
has a robust partition into 3, 5 and 7 communities.
b. Structured clusters from pre-existing clusters
We present the clustering assignments after using MS to obtain our initial partition into clusters. The pre-existing
and structured cluster results for three clusters (Fig. S4), five clusters (Figs. 3D, S4) and seven clusters (Fig. S6).
A finer clustering into seven groups (see Fig. S6) divides the ligands into three groups: high response (yellow,
green, brown) {BTC, EGF, EPR, FGF-1, FGF-2, HGF, HRG} and lower response (blues) {IGF1, IGF2, INS} and {
NGF-β, PDGF-BB, SCF, VEGF175}. The assignment of cell types is remarkably similar to the five cluster results.
The exception cell lines are: HCC1419 (green to brown), and ZR-75-30 (green to the new seventh cluster). Given this
consistency, we restrict to mechanistic interpretation of the five cluster case.
4. Comparison of implementations
When we employ our method assuming no initial clusterings, the integer optimization is learning the values, 0 or
1, for an array of size c × c × l × l (where c = #cell lines and l = # ligands). When we use an initial clustering,
CPLEX uses the same branch and cut algorithm on an array of size c× l× k, where c = #cell lines, l = #ligands and
k = #clusters, so the array is much smaller for the pre-existing clustering implementation. We show a comparison of
the performance of the two implementations in Fig. S7
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FIG. S4. A. The clustering assignments are represented by yellow, green and blue squares. B. The tensor clustering are a close
approximation to the clusters obtained with MS.
5. Code for constrained clustering
The following pieces of Matlab code generate the constraints on the tensors that encode the clustering assignment,
under the rectangle clusterings condition. Assume we have a dataset of size n×m×· · ·×o and we wish to cluster into
rectangular-shaped clusters using the first two indices. First, reshape the data into a three-dimensional array, Tensr,
by vectorizing the 3rd, 4th, . . . , indices into a multi-index of size p. Then, the following code makes the similarity
tensor with respect to cosine dissimilarity.
[n m p] = size(Tensr);
C = zeros(n,n,m,m);
for i = 1:n; for j = 1:n; for k = 1:m; for l = 1:m;
v1 = zeros(p,1); v2 = zeros(p,1);
for ii = 1:p;
v1(ii) = Tensr(i,k,ii); v2(ii) = Tensr(j,l,ii);
end
C(i,j,k,l) = 1 - dot(v1,v2)/(norm(v1,2)*norm(v2,2));
end end end end
Next we encode the constraints on the tensor which encodes the partition of the data set. It is constructed as a
sparse array, i.e. by specifying row and column indices Vrow and Vcol, and values Vval of all non-zero entries. The
16
Five Clusters from Preliminary RMST
BT
C
EG
F
EP
R
FG
F-1
FG
F-2 HG
F
HR
G
IGF
-I
IGF
-II INS
NG
F-b
eta
PD
GF
-BB SC
F
VE
GF
165
MCF7
SK-BR-3
MDA-MB-231
AU565
BT-20
BT-474
BT-483
BT-549
CAMA-1
HCC1395
HCC1419
HCC1428
HCC1569
HCC1806
HCC1937
HCC1954
HCC202
HCC38
HCC70
Hs 578T
MDA-MB-134-VI
MDA-MB-157
MDA-MB-175-VII
MDA-MB-361
MDA-MB-415
MDA-MB-436
MDA-MB-453
MDA-MB-468
T47D
UACC-812
UACC-893
ZR-75-1
ZR-75-30
184B5
HCC1187
HCC1500
FIG. S5. Five clusters from Markov Stability
Seven Clusters from Preliminary RMST
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FIG. S6. Seven clusters from Markov Stability.
lower and upper bounds for each linear constraints are organized into the vectors lb and ub respectively.
t = 1;
for i = 1:n; for j = 1:n; for k = 1:m; for l = 1:m;
if (i ~= j) || (k ~= l);
W = vectorize(n,i,j,k,l);
Vrow(w) = t; Vcol(w) = W;Vval(w) = 1;
w = w+1;
W = vectorize(n,j,i,l,k);
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
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FIG. S7. Computational complexity of two implementations with eight ligands and a varying number of cell lines.
lb(t) = 0; ub(t) = 0;
t = t+1;
end
if (k ~= l);
W = vectorize(n,i,j,k,l);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = vectorize(n,i,j,l,k);
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
lb(t) = 0; ub(t) = 0;
t = t+1;
% opposite diagonals must be same
end
if (i ~= j);
W = vectorize(n,i,j,k,l);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = vectorize(n,j,i,k,l);
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
lb(t) = 0; ub(t) = 0;
t = t+1;
end
if (k ~= l);
W = vectorize(n,i,j,k,l);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = vectorize(n,j,i,k,k);
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
lb(t) = 0; ub(t) = 1;
t = t+1;
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% vertical conditions
end
if (i ~= j);
W = vectorize(n,i,j,k,l);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = vectorize(n,i,i,k,l);
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
lb(t) = 0; ub(t) = 1;
t = t+1;
% horizontal conditions
end
end end end end
for i = 1:n; for k = 1:m;
W = vectorize(n,i,i,k,k);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
lb(t) = 0; ub(t) = 0;
t = t+1;
end end
for i1 = 1:n; for i2 = 1:n; for i3 = 1:n;
for k1 = 1:m; for k2 = 1:m; for k3 = 1:m;
if (((i1 ~= i2) || (k1 ~= k2)) && ((i2 ~= i3) || (k2 ~= k3)) && ((i1 ~= i3) || (k1 ~= k3)));
W = vectorize(n,i1,i3,k1,k3);
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
W = vectorize(n,i1,i2,k1,k2);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = vectorize(n,i2,i3,k2,k3);
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
lb(t) = 0; ub(t) = 2;
t = t+1;
end end end end end end end
maxt = t-1;
V = sparse(Vrow,Vcol,Vval,maxt,n*n*m*m);
Now complete the optimization using CPLEX, feeding the above constraints into the model alongside a penalty
parameter that controls the number of clusters. The function vectorize, used above, combines the multi-index into
a single index:
function t = vectorize(n,i,j,k,l);
m = 14; % for example
i1 = n*m*m*(i-1); j1 = m*m*(j-1); k1 = m*(k-1); l1 = l;
t = i1+j1+k1+l1;
For clustering based on pre-existing clusters, we generate the constraints imposed using the following Matlab code.
Assume we are clustering based on 2 indices of sizes n and m, and that the preliminary clustering returned nclu
clusters. As before, the lower and upper bounds on the conditions are organized into the vectors lb and ub.
w = 1; t = 1;
for i = 1:n; for j = 1:m;
for k = 1:nclu;
W = nclu*m*(i-1) + nclu*(j-1) + k;
% turn i,j,k coordinates into a vector
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Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
end
lb(t) = 1; ub(t) = 1;
t = t+1;
end end
the vector at position (i,j) has entries which sum to 1
for i = 1:n; for j = 1:n; for k = 1:m; for l = 1:m;
if (i ~= j) && (k ~= l) ;
for r = 1:nclu;
W = nclu*m*(i-1) + nclu*(k-1) + r;
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = nclu*m*(j-1) + nclu*(l-1) + r;
Vrow(w) = t; Vcol(w) = W; Vval(w) = 1;
w = w+1;
W = nclu*m*(i-1) + nclu*(l-1) + r;
Vrow(w) = t; Vcol(w) = W; Vval(w) = -1;
w = w+1;
lb(t) = -1; ub(t) = 1;
t = t+1;
end end
end end end end
maxt = t-1;
make sparse array of the constraints:
Vnew = sparse(Vrow,Vcol,Vval,maxt,n*m*nclu);
Appendix C: Models
1. Models of the MAPK pathway
The MAP Kinase pathway has been widely studied. Models have focused on various features of the cascade, such
as its three-tier phosphorylation feedback structure [8, 9]. The activation profile of these kinases is directly related
to cellular decisions and fates [10–13]. The AKT pathway has been modeled by EGF-dependent activation, including
phosphorylation of AKT (pAKT) and its downstream intracellular proteins [14]. Few models of crosstalk between
ERK and AKT exist. One model was created for studying PC12 cells, and they found that AKT acts as a low-pass
filter which decouples the EGF signal [15]. Another model was created to study HEK293 cells in the presence of a
MEK inhibitor; they found crosstalk is reinforced between Ras and PI3K [16]. Another model found that JNK is
regulated by AKT and MAPK feedbacks in these pathway [17]. Chen and co-authors constructed and analyzed an
ErbB model focusing on the receptor dynamics and early activation response of the MAPK and AKT pathways in
response to ligands in A431 or H1666 cells [13]; however their model was unidentifiable, meaning there were an infinite
number of parameter values to fit the data [13]. Weakly activated models of MAPK activation cascades with optimal
amplification under a variety of stimuli were analyzed in [18].
2. All wiring diagrams
We consider all possible wiring diagrams to describe the interactions between the receptor, the Erk pathway and
the Akt pathway. These can be written as a wiring-diagram where we assume an arrow exists between the ligand L
and receptor R:
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Number of arrows Total number of networks Number of networks we consider
All 34 = 81 15
0
(
4
0
) · 20 = 1 None
1
(
4
1
) · 21 = 8 None
2
(
4
2
) · 22 = 24 3
3
(
4
3
) · 23 = 32 8
4
(
4
4
) · 24 = 16 4
TABLE III. In total, we consider 15 network topologies: those that are biologically plausible given the data. There are different
possible kinetics for each model: mass-action or Michaelis-Menten. This gives 15× 2 = 30 possible models. Furthermore, seven
of these include inhibition (a) which we model via either: blocking or removal (described in the text). Accounting for all our
kinetic models gives a total of 44 models.
pErk
Ligand
Receptor
pAkt
We first consider all possible network topologies with interactions between the variables R, E and A. There are
three possibilities for the directed interaction from one variable to another: positive (→), negative (a), or no significant
interaction (no arrow). There are six potential directed interactions in the network which give a total of 36 = 729
networks.
Many of these networks can be ruled out. The data shows some response in pERK and pAKT for each stimuli,
therefore we require that both pERK and pAKT have at least one arrow coming into each of these (to ensure a
response). Given this restriction from the data, we can eliminate many networks, for example a network where the
receptor inhibits pAKT and pERK is biologically infeasible. We also do not have dynamic data of the phosphorylated
receptor, therefore we cannot distinguish a network topology that has an arrow feeding back from the phopho-form to
the receptor; thus we fix the interaction from pERK to R and pAKT to R to none (no arrow). All of these restrictions
produce Table III.
Based on these wiring diagrams, we now consider different possible kinetics for each arrow, summarized in the
Table, and described in the next subsection.
3. Construction of mechanistic models
We construct systems of ordinary differential equation models to describe interaction dynamics between the receptor
(R), pAKT (A) and pERK (E). The equation describing the evolution of the phosphorylated receptor is dR/dt =
αL(Rtot − R) − δR. The total amount of receptor, Rtot, is estimated from the receptor abundance data. The
unphosphorylated receptor is given by (Rtot−R). The parameter α determines the rate at which it is phosphorylated
by the ligand dose (L = 1 or 100 ng/ml). The time evolution of pERK and pAKT can be activated by R. There are
two other equations, dE/dt and dA/dt, which describe the change in the phosphorylation (in fold change) of A and E
with respect to time. Crosstalk between the ERK and AKT pathways is encoded by interactions between pERK and
pAKT, which can either activate or inhibit the other pathway. Activation terms are modeled using either mass action
or Michaelis-Menten kinetics. We consider two types of inhibition: blocking through a saturation term or through a
removal term using mass action kinetics.
Without data from receptor dynamics, we write the change in phosphorylated receptor (in arbitrary units) as a
function of time as:
R′ = αL(Rtot −R)− δR,
where αL(Rtot−R) describes the fraction of non-phosphorylated receptor that becomes phosphorylated at some rate
proportional to the ligand L, and δ is the rate at which R is de-phosphorylated.
The other two equations, E′ and A′ describe the change in the phosphorylation (in fold change) of A and E with
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Ligand Associated Receptors
BTC ErbB1, ErbB4
EGF ErbB1
EPR ErbB1, ErbB4
FGF-1 FGFR-1, FGFR-2, FGFR-3, FGFR-4
FGF-2 FGFR-1, FGFR-2, FGFR-3, FGFR-4
HGF cMET
HRG ErbB4
IGF-1 IGF1R
IGF-2 IGF1R, IGF2R
INS InsR
NGF-beta TrkA
PDGF-BB PDGFRa, PDGFRb
SCF c-Kit
VEGF165 VEGFR-1, VEGFR-2, VEGFR-3
TABLE IV. Receptors associated to each ligand
respect to time. These equations change based on the assumed interactions, each different set of equations describes
a different mechanistic model.
We assume that activation is either via mass-action kinetics or Michaelis-Menten kinetics, and that inhibition is
either via removal or blocking. For example, if we consider the model R→ E → A, R a A, we can write this as:
R′ = αL(Rtot −R)− δR, (C1)
E′ =
k1R
Km1 +R
− δE, (C2)
A′ =
k2E
Km2 + E
− k3AR− δA, (C3)
where the blue denotes the Michaelis-Menten term (ignoring the blue is mass-action), and the red term k3AE describes
inhibition of A as a removal interaction. However, when A is inhibiting by blocking, now the red term is written in a
the following form:
R′ = αL(Rtot −R)− δR, (C4)
E′ =
k1R
Km1 +R
− δE, (C5)
A′ =
(
k2E
Km2 + E
)(
k3
k3 +R
)
− δA. (C6)
We summarize the 44 models analyzed in more detail in Fig. S8.
Appendix D: Model identification
1. Estimating the total abundance of receptor, Rtot
Our mechanistic analysis requires us to estimate the total abundance of receptor (both phosphorylated and un-
phosphorylated) prior to the addition of any ligand. We do this based on the Receptor Abundance Data from [19,
Figure 1]. Each ligand has one or more receptors associated to it, as shown in Table IV.
Each experiment involves a cell line and a ligand. For each cell line/ligand pair, we estimate the receptor abundance
by averaging the receptor abundances for that cell line, for each of the receptors associated to the ligand. We do this
averaging over all receptor, cell line pairs for which we have data.
We then estimate the receptor abundance for a cluster by averaging the values obtained above for each cell line,
ligand pair that is present in the cluster.
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FIG. S8. Mechanistic models of breast cancer cell lines. The name of network model is indexed first by whether it is a
two arrow (A), three arrow (B), or four arrow (C) model. The second index assigns a number to each network topology.
Each network can be further subdivided to describe a model with mass action kinetics (1 in third index) and a model with
Michaelis-Menten kinetics (2 in third index). Any network with inhibition (a) has 4 models considered: mass action removal
(1 in third index), Michaelis-Menten removal (2 in third index), mass action blocking (1b in third index), or Michaelis-Menten
removal (2b in third index). Stars next to the model name are globally structurally identifiable models, all other models are
locally structurally identifiable.
2. Identifiability analysis
Before estimating model parameters from the data, we determine whether a model is identifiable. Models that
are globally identifiable have parameters that are uniquely identifiable under ideal data conditions. Models that
are locally identifiability have a finite number of indistinguishable parameter values. Since we only have time-course
measurements for A and E, we use a differential algebra approach for eliminating the species R. We test identifiability
using the algorithm DAISY [20]. All of our models are locally, if not globally identifiable given the experimental data.
Globally identifiable models are denoted by brown boxes in Fig. S8.
3. Parameter estimation
We estimate parameters using the average time-course for each cluster. The model simulated at a parameter vector
θ gives a vector of model predictions of E and A at dose L and time point tj and data D is the set of normalised
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FIG. S9. Example output of the Squeeze and Breathe parameter estimation algorithm. A: Sequence of posteriors for each
parameter after each iteration. B: Convergence of the objective function. The plot shows the error of best parameter sets after
each iteration. C: Final distribution of the parameters after convergence. The red star marks the value of the parameter with
the lowest error. D and E: Time course of the model with the best parameters for one cluster.
measurements of Eˆ and Aˆ. The squared sum of errors of the model with parameter set θ is:
ED(θ) =
∑
L∈ doses
∑
tj
(
Aˆij(tj ; L)−Aij(tj ; θ, L)
)2
+
(
Eˆij(tj ; L)− Eij(tj ; θ, L)
)2
.
We seek the parameter set θ∗ that minimises the discrepancy between the model and the data:
θ∗ = argmin
θ
ED(θ), subject to θ∗ ≥ 0. (D1)
We find θ∗ using the Squeeze-and-Breathe (SB) evolutionary optimisation algorithm [21], available as code here
https://people.maths.ox.ac.uk/beguerisse/#squeezecode. Given an initial estimate of the distribution of the parame-
ter values (a ‘prior’). SB generates a large number of parameter sets using Monte-Carlo simulation. These points are
used as the starting guess for a local minimisation of ED(θ) using a derivative free method such as Nelder-Mead [22].
The local minima are ranked and the best points are used to recompute the distribution of the parameters (the ‘pos-
terior’). These new posteriors are used as priors in a new iteration of the algorithm, which again looks for new local
minima and keeps the best. This process goes on until the error function converges. One of the key advantages of SB
is that it can handle situations where little is known about the parameter values by efficiently exploring the parameter
space, even venturing to regions outside the original prior (for this reason the posteriors are not true posteriors in the
Bayesian sense). Figure S9 shows an example for the type of output produced by SB.
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FIG. S10. Values of the AIC for the models ranked first to tenth in each of the five clusers depicted in Fig. 4 of the Main Text.
The dashed red line indicates the cutoff for the models in Fig. 4.
4. Model selection
We perform model selection on the 40 models and 5 clusters using the Akaike Information Criterion with a correction
for finite sample size (AICc) [23]. For a given model i with pi parameters,
AICci = n ln(nRSSi) + 2pi +
2pi(pi + 1)
n− (pi + 1) ,
where n is the number of observations and RSSi is the residual sum of squares of the model. The AICc balances how
well the model fits the data with the complexity of the model (the number of parameter values). The lowest AICci
is the preferable model. Figure S10 shows the AIC scores of the models for each cluster, ranked from first (best) to
tenth.
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